Niox Group PLC
LSE:NIOX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
58
75.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Niox Group PLC
Niox Group PLC
Accounts Payable
Niox Group PLC
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Niox Group PLC
LSE:NIOX
|
Accounts Payable
£900k
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Accounts Payable
$11.8m
|
CAGR 3-Years
128%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Accounts Payable
$103k
|
CAGR 3-Years
-64%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Accounts Payable
$5.7m
|
CAGR 3-Years
47%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Accounts Payable
£17.8m
|
CAGR 3-Years
45%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Accounts Payable
£123.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
Niox Group PLC
Glance View
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.
See Also
What is Niox Group PLC's Accounts Payable?
Accounts Payable
900k
GBP
Based on the financial report for Jun 30, 2024, Niox Group PLC's Accounts Payable amounts to 900k GBP.
What is Niox Group PLC's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-47%
Over the last year, the Accounts Payable growth was -61%. The average annual Accounts Payable growth rates for Niox Group PLC have been -6% over the past three years , -47% over the past five years .
You don't have any saved screeners yet
